Company Filing History:
Years Active: 2005-2008
Title: Kagehiro Amano: Innovator in Hemophilia Treatment
Introduction
Kagehiro Amano is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of treatments for hemophilia. With a total of two patents to his name, Amano's work focuses on innovative solutions that enhance the efficacy of factor VIII proteins.
Latest Patents
Amano's latest patents revolve around the inactivation resistant factor VIII. The present invention provides novel purified and isolated nucleic acid sequences encoding procoagulant-active FVIII proteins. These nucleic acid sequences encode amino acid sequences corresponding to known human FVIII sequences, wherein residue Phe309 is mutated. Additionally, the sequences also encode amino acid sequences corresponding to known human FVIII sequences, wherein the APC cleavage sites, Arg336 and Ile562, are mutated. Furthermore, the sequences encode amino acid sequences corresponding to known human FVIII sequences, wherein the B-domain is deleted, the von Willebrand factor binding site is deleted, a thrombin cleavage site is mutated, and an amino acid sequence spacer is inserted between the A2- and A3-domains. The invention also includes methods of producing the FVIII proteins, nucleotide sequences encoding such proteins, pharmaceutical compositions containing the nucleotide sequences or proteins, as well as methods of treating patients suffering from hemophilia.
Career Highlights
Kagehiro Amano is affiliated with the University of Michigan, where he continues to advance his research and innovations. His work has garnered attention for its potential to improve treatment outcomes for individuals with hemophilia.
Collaborations
Amano has collaborated with esteemed colleagues, including Randal J Kaufman and Steven W Pipe, to further enhance the impact of his research in the field of biotechnology.
Conclusion
Kagehiro Amano's contributions to the development of inactivation resistant factor VIII proteins represent a significant advancement in hemophilia treatment. His innovative approach and dedication to research continue to inspire progress in the medical community.